Table 3.
Trial | % Women | Primary Outcome | P Value for Difference in Primary Endpoint Between Women and Men |
---|---|---|---|
ARISTOTLE (apixaban) | 35 | Stroke or systemic embolism | 0.60 |
RE-LY (dabigatran) | 37 | Stroke or systemic embolism | 0.24 |
ROCKET AF (rivaroxaban) | 39.7 | Stroke or systemic embolism | 0.927 |